

Technology Advisory Committee A Interests Register

Topic [ID3908] Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence

Publication Date: 26 October 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Pippa Corrie	Clinical Expert	Direct financial, Direct non-financial interest and Indirect interests	<p>Pippa Corrie declared the following:</p> <p>Direct financial interest - I have received payment for attending advisory boards conducted in the last 2 years by MSD & BMS. I have received speaker fees from BMS, MSD, Novartis, Pierre Fabre relating to melanoma systemic therapies</p> <p>Direct non-financial interest - I am the PI for the Keynote 716 trial being conducted at Addenbrooke's hospital as a participating site</p> <p>Indirect interest - I am PI for other commercial and non-commercial sponsored trials evaluating melanoma systemic therapies in both the</p>		09/08/2022		It was agreed that this declaration would not prevent Pippa from participating in the discussion,

			adjuvant and metastatic setting				
Mark Harries	Clinical Expert	Direct financial interest	Over the last 5 years Mark has received honoraria from MSD for advisory boards, speakers' fees and also received support towards the costs of attending medical conferences. He has similar relationships with multiple Pharma (Exact Sciences, Pierre Fabre, BMS, Novartis, Pfizer, Roche, Eisai, Gilead).		13/07/2021		It was agreed that this declaration would not prevent Mark from participating in the discussion,